Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, Stephanie J., Kukreja, Manisha, Wang, Tao, Giralt, Sergio A., Szer, Jeffrey, Arora, Mukta, Woolfrey, Ann E., Cervantes, Francisco, Champlin, Richard E., Gale, Robert Peter, Halter, Joerg, Keating, Armand, Marks, David I., McCarthy, Philip L., Olavarria, Eduardo, Stadtmauer, Edward A., Abecasis, Manuel, Gupta, Vikas, Khoury, H. Jean, George, Biju, Hale, Gregory A., Liesveld, Jane L., Rizzieri, David A., Antin, Joseph H., Bolwell, Brian J., Carabasi, Matthew H., Copelan, Edward, Ilhan, Osman, Litzow, Mark R., Schouten, Harold C., Zander, Axel R., Horowitz, Mary M., Maziarz, Richard T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2954751/
https://ncbi.nlm.nih.gov/pubmed/18664621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141689
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados